Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Emerging evidence on the efficacy of intracameral moxifloxacin in the reduction of postoperative endophthalmitis

Search Title by author or title

Session Details

Session Title: Endophthalmitis/ Ocular Infections/ Miscellaneous

Session Date/Time: Tuesday 10/10/2017 | 08:00-10:30

Paper Time: 08:12

Venue: Room 4.6

First Author: : M.Mouttapa INDIA

Co Author(s): :    J. Christy                    

Abstract Details

Purpose:

To study the incidence of endophthalmitis post cataract surgery, 1 year before and after the introduction of Intracameral moxifloxacin.

Setting:

Aravind eye hospital, Pondicherry,South India.

Methods:

Endophthalmitis registry from April 2015 to March 2016 was analysed and compared to the previous one year data( April 2014 to March 2015) before the initiation of Intracameral (IC) moxifloxacin.The eyes which did not receive IC moxifloxacin were included in Group1 and those which received IC moxifloxacin were included in group2 . Outcome measures compared were, Total endophthalimitis rate, Endophthalmitis rate in Phacoemeulsification, manual small incision cataract surgery (MSICS) and in eyes which had intraoperative complications.

Results:

Out of 42777 eyes in Group1 which did not receive IC moxifloxacin, 22 developed endophthalmitis (0.05%) and of 42866 eyes in Group2,11 developed endophthalmitis (0.02%). Among eyes which underwent phacoemulsification, endophthalmitis rate significantly reduced from 0.09% in group 1(11663) which didn’t receive IC moxifloxacin to 0.008% in group 2(12074) which received IC moxifloxacin (P<0.001). Among MSICS eyes, endophthalmitis rate remained similar at 0.03% in both groups.Noticeably, endophthalmitis rate among eyes which had intraoperative complications was none in group 2 (690 eyes) which received IC moxifloxacin compared to 0.3% in group 1 (633eyes) which did not receive the prophylaxis.

Conclusions:

The use of intracameral moxifloxacin at the end of cataract surgery as an endophthalmitis prophylaxis has led to marked reduction in the overall endophthalmitis rate and more significantly in eyes undergoing phacoemulsification and with intraoperative complications. There was no difference in the MSICS arm as claimed in other studies. Moxifloxacin appears to be an effective option for surgeons electing IC antibiotic prophylaxis considering its easy availability, cost effectiveness and absence of any reported complications.

Financial Disclosure:

NONE

Back to previous